<DOC>
	<DOCNO>NCT00567190</DOCNO>
	<brief_summary>This study Phase III , randomize , double-blind , placebo-controlled , multicenter international clinical trial . Patients human epidermal growth factor receptor 2 ( HER2 ) -positive metastatic breast cancer ( MBC ) receive chemotherapy biological therapy ( include approve investigational tyrosine kinase/HER inhibitor vaccine ) metastatic disease eligible study . Patients could receive one prior hormonal treatment MBC . Patients may receive systemic breast cancer treatment neo-adjuvant adjuvant setting , provide patient experience disease-free interval ( DFI ) ≥ 12 month completion adjuvant systemic treatment ( exclude hormonal therapy ) metastatic diagnosis . Patients may receive trastuzumab and/or taxane neo-adjuvant adjuvant treatment .</brief_summary>
	<brief_title>A Study Evaluate Pertuzumab + Trastuzumab + Docetaxel v . Placebo + Trastuzumab + Docetaxel Previously Untreated HER2-positive Metastatic Breast Cancer ( CLEOPATRA )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease , candidate chemotherapy . Patients measurable nonmeasurable disease eligible ( locally recurrent disease must amenable resection curative intent ; patient de novo Stage IV disease eligible ) . Human epidermal growth factor receptor 2 ( HER2 ) positive metastatic breast cancer ( MBC ) . Age ≥ 18 year . Left ventricular ejection fraction ( LVEF ) ≥ 50 % baseline ( within 42 day randomization ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) = 0 1 . For woman childbearing potential , agreement use effective form contraception continue use duration study treatment 6 month last dose study treatment . Signed , write informed consent obtain prior study procedure . History anticancer therapy MBC ( exception one prior hormonal regimen MBC ) . History approve investigative tyrosine kinase/HER inhibitor breast cancer treatment set , except trastuzumab use neoadjuvant adjuvant setting . History systemic breast cancer treatment neoadjuvant adjuvant set diseasefree interval completion systemic treatment ( exclude hormonal therapy ) metastatic diagnosis &lt; 12 month . History persistent Grade ≥ 2 hematologic toxicity result previous adjuvant therapy . Current peripheral neuropathy National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) Version 3.0 , Grade ≥ 3 randomization . History malignancy within last 5 year , except carcinoma situ cervix basal cell carcinoma . Current clinical radiographic evidence central nervous system ( CNS ) metastases . Computed tomography ( CT ) magnetic resonance imaging ( MRI ) scan brain mandatory case clinical suspicion brain metastasis . History exposure cumulative dos anthracyclines . Current uncontrolled hypertension unstable angina . History congestive heart failure ( CHF ) New York Heart Association ( NYHA ) criterion , serious cardiac arrhythmia require treatment . History myocardial infarction within 6 month randomization . History LVEF decline 50 % prior trastuzumab neoadjuvant adjuvant therapy . Current dyspnea rest due complication advance malignancy , diseases require continuous oxygen therapy . Inadequate organ function within 28 day prior randomization . Current severe , uncontrolled systemic disease . Major surgical procedure significant traumatic injury within 28 day prior study treatment start anticipation need major surgery course study treatment . Pregnant lactating woman . History receive investigational treatment within 28 day randomization . Current known infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . Receipt intravenous ( IV ) antibiotic infection within 14 day randomization . Current chronic daily treatment corticosteroid ( exclude inhale steroid ) . Known hypersensitivity study drug . Assessed investigator unable unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Herceptin</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>MBC</keyword>
	<keyword>Taxotere</keyword>
	<keyword>HER2</keyword>
	<keyword>HER2 positive breast cancer</keyword>
	<keyword>HER2 + breast cancer</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>HER2-positive metastatic breast cancer</keyword>
</DOC>